FDA Approves Idecabtagene vicleucel for Relapsed or Refractory Multiple Myeloma

$FDA Approves Idecabtagene vicleucel for Relapsed or Refractory Multiple Myeloma$

On April 4, the US Food and Drug Administration (FDA) approved idecabtagene vicleucel for the treatment of adult patients with relapsed or refractory multiple myeloma after 2 or more prior lines of therapy including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.

For more information read the Bristol Myers Squibb announcement.

Posted 4/9/2024